ライフサイエンスコーパス: 6-MP

1 6-MP ingestion habits examined included: takes 6-MP with

2 6-MP should be part of the initial treatment regimen for

3 6-MP use before or at conception or during pregnancy app

4 6-MP was more effective than placebo ( P < 0.05) at prev

5 6-MP, 50 mg daily, was more effective than placebo at pr

6 leukocyte transmigration was inhibited after 6-MP/6-T-GTP treatment.

7 s study was to analyze the safety of AZA and 6-MP and steroid reduction in this age group.

8 AZA and 6-MP were well tolerated in 82% of patients; of these, p

9 d total therapeutic dose of azathioprine and 6-MP.

10 ssociation between 6-MP ingestion habits and 6-MP adherence, red cell thioguanine nucleotide (TGN) le

11 Because 6-MP and its derivative 6-thioguanosine-5'-triphosphate

12 This study examines the association between 6-MP ingestion habits and 6-MP adherence, red cell thiog

13 osticators, there was no association between 6-MP ingestion habits and relapse risk (6-MP with food:

14 s to capture leukocytes, also was reduced by 6-MP/6-T-GTP.

15 Certain 6-MP ingestion habits were associated with nonadherence

16 ar incorporation of DNA-TGN for 6-TG but for 6-MP significantly reduced DNA-TGN in TPMT-induced compa

17 Indeed, 6-MP and 6-T-GTP decreased Rac1 activation in endothelia

18 led by the ADSS inhibitor 6-mercaptoethanol (6-MP).

19 hough the thiopurine drugs 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are well established agen

20 rrent trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for the prevention of

21 iopurines azathioprine and 6-mercaptopurine (6-MP) are effective immune modulators and cytotoxic agen

22 Azathioprine (AZA) and 6-mercaptopurine (6-MP) are used in pediatric patients with ulcerative col

23 ioprine and its metabolite 6-mercaptopurine (6-MP) are well established immunosuppressive drugs.

24 l experience suggests that 6-mercaptopurine (6-MP) is effective therapy for children with active ster

25 uate potential toxicity of 6-mercaptopurine (6-MP), we reviewed the records of 485 patients who had r

26 eated with azathioprine or 6-mercaptopurine (6-MP).

27 rs [azathioprine (AZA), or 6-mercaptopurine (6-MP)] and newer biologic agents (infliximab, adalimumab

28 generally instructed to take mercaptopurine (6-MP) in the evening and without food or dairy products.

29 of continuation therapy with mercaptopurine (6-MP) and asparaginase (L-ASP).

30 Moreover, 6-MP and 6-T-GTP selectively decreased TNF-alpha-induced

31 important component of the mode of action of 6-MP is inhibition of purine de novo synthesis (PDNS) th

32 Addition of 6-MP to a regimen of corticosteroids significantly lesse

33 ticenter trial evaluating the combination of 6-MP and prednisone as therapy for children with newly d

34 For equitoxic doses of 6-MP, equivalent levels of MeTIMP correlated with equiva

35 a underscore the anti-inflammatory effect of 6-MP and 6-T-GTP on endothelial cells by blocking Rac1 a

36 mechanism underlying the protective role of 6-MP in endothelial cell activation is investigated.

37 AZA or 6-MP was tolerated in 51 of 95 patients (54%) without ad

38 reased risk of lymphoma with azathioprine or 6-MP therapy, an increased risk was not observed in this

39 se patients not treated with azathioprine or 6-MP, the relative risk of lymphoma among the 1465 infla

40 ncluded 441 children with ALL receiving oral 6-MP for maintenance.

41 e centers randomized 131 patients to receive 6-MP (50 mg), mesalamine (3 g), or placebo daily in a do

42 77% (95% CI, 61%-91%) in patients receiving 6-MP, mesalamine, and placebo, respectively.

43 Future recommendations regarding 6-MP intake during maintenance therapy for childhood ALL

44 ween 6-MP ingestion habits and relapse risk (6-MP with food: hazard ratio [HR], 0.7; 95% CI, 0.3 to 1

45 Commonly practiced restrictions surrounding 6-MP ingestion might not influence outcome but may hinde

46 analyzed as to whether the patient had taken 6-MP before, or at the time of, conception.

47 6-MP with versus never with dairy, and takes 6-MP in the evening versus morning versus varying times.

48 akes 6-MP with versus never with food, takes 6-MP with versus never with dairy, and takes 6-MP in the

49 MP ingestion habits examined included: takes 6-MP with versus never with food, takes 6-MP with versus

50 ation between red cell TGN levels and taking 6-MP with food versus without (206.1 +/- 107.1 v 220.6 +

51 ents who had their pregnancies before taking 6-MP.

52 women who had taken or were currently taking 6-MP to controls.

53 ts were associated with nonadherence (taking 6-MP with dairy [odds ratio (OR), 1.9; 95% CI, 1.3 to 2.

54 ections among male or female patients taking 6-MP compared with controls (RR = 0.85 [0.47-1.55], P =

55 both groups, only 9% of the remitters in the 6-MP group relapsed compared with 47% of controls (P = 0

56 In the 6-MP group, the duration of steroid use was shorter (P<0

57 aminotransferase activity were noted in the 6-MP group.

58 trated a 4.4-fold increase in sensitivity to 6-MP.

59 cytotoxic potential in patients treated with 6-MP, because different levels of DNA-TGN may be associa

60 /-2 years) were randomized to treatment with 6-MP (1.5 mg x kg(-1) x day(-1)) or placebo within 8 wee

61 Study treatment with 6-MP or placebo continued for 18 months.